HLA-DRA Leu242Val: The Molecular Gatekeeper of Peanut Antigen Presentation
At the heart of every allergic reaction lies a decision made long before the first
exposure: which proteins should the immune system tolerate, and which should trigger
a response? That decision is governed by the HLA class II system11 HLA class II system
Human Leukocyte
Antigen class II molecules are protein complexes on the surface of antigen-presenting
cells that display peptide fragments to CD4+ T cells, shaping immune tolerance vs
activation. rs7192 introduces a
missense change — Leucine to Valine at codon 242 (Leu242Val) — in the HLA-DRA alpha
chain, one of the two protein subunits that form HLA-DR molecules. This single amino
acid change alters the structural conformation of the antigen-presenting groove and
helps tag HLA class II haplotypes associated with peanut allergy
and broader immune-mediated conditions.
The Mechanism
HLA-DR molecules are heterodimers — an alpha chain (encoded by HLA-DRA) paired with
one of several beta chains (encoded by HLA-DRB1, DRB3, DRB4, or DRB5). The peptide-binding
groove formed by the two chains determines which protein fragments the immune system is
presented for T-cell education during thymic development and peripheral tolerance
maintenance. Leucine 242 sits in the alpha-1 domain22 alpha-1 domain
The membrane-distal domain of
the HLA-DRA alpha chain that forms one wall of the peptide-binding groove,
a region critical to groove shape and peptide-binding specificity.
Additionally, rs7192 acts as a quantitative trait locus for DNA methylation33 quantitative trait locus for DNA methylation
A genetic variant that influences how nearby genes are methylated, affecting their
expression levels at CpG sites in both
HLA-DRB1 and HLA-DQB1.
The Evidence
Hong et al. (2015)44 Hong et al. (2015)
Genome-wide association study identifies peanut allergy-specific
loci and evidence of epigenetic mediation in US children. Nature Communications, 2015
conducted the first GWAS of well-characterised food allergy in 2,197 US participants
of European ancestry. rs7192 reached genome-wide significance (p=5.5×10⁻⁸) in the
discovery phase and was independently replicated in an additional European cohort.
The per-allele odds ratio for peanut allergy was approximately 1.7, placing this
SNP among the strongest common genetic risk factors identified for the condition.
Crucially, the association was accompanied by genome-wide significant differential
DNA methylation at multiple CpG sites within HLA-DQB1 and HLA-DRB1.
A complementary line of evidence comes from Guéant et al. (2015)55 Guéant et al. (2015)
HLA-DRA
variants predict penicillin allergy in genome-wide fine-mapping genotyping.
Journal of Allergy and Clinical Immunology, 2015,
which fine-mapped the HLA-DRA locus in 387 beta-lactam allergy cases and 1,124
controls from Spain (replicated in an Italian cohort). The rs7192 missense variant
was significantly associated with allergy to penicillins and amoxicillin
(p=7.4×10⁻⁶ discovery; p=6.0×10⁻⁴ replication). The study specifically noted
that the variant is "predicted to influence alpha-chain conformation."
Asai et al. (2018)66 Asai et al. (2018)
Canadian peanut allergy GWAS meta-analysis. Journal of
Allergy and Clinical Immunology, 2018
integrated data from 8 studies (>7,800 subjects total) and confirmed the HLA-DQB1/
DRB1 region as the primary peanut allergy locus — the same locus tagged by rs7192
and its companion SNP rs9275596. Importantly, the association was independent of
asthma genetic architecture, establishing peanut allergy as a genetically distinct
trait rather than a subset of atopy.
Practical Actions
Because rs7192 tags the same HLA risk block as rs9275596 (the primary peanut allergy GWAS signal), the practical implications are closely aligned: individuals carrying one or two T alleles carry a modestly elevated prior probability of peanut allergy through HLA class II-mediated sensitization mechanisms. The landmark LEAP trial showed that early peanut introduction (before 11 months) can completely override this HLA-mediated genetic risk by driving protective IgG4 rather than sensitizing IgE responses. For individuals who have already developed peanut allergy, HLA class II haplotype status predicts superior response to peanut oral immunotherapy — carriers of the risk haplotype achieve higher rates of desensitization than non-carriers.
Interactions
rs7192 is part of the same HLA-DR/DQ risk block as rs9275596, its companion tag SNP from the peanut allergy GWAS. These two variants operate within the extended HLA class II haplotype architecture spanning chromosome 6p21.32. The HLA region also harbours rs7454108 (tagging HLA-DQ8, associated with celiac disease and type 1 diabetes) and rs2187668 (tagging HLA-DQ2.5, the primary celiac disease haplotype). Together, these tag SNPs define the major HLA class II susceptibility landscape for immune-mediated conditions — a person's full HLA class II profile across these loci provides a more complete picture of their antigen-presentation capabilities than any single SNP alone.